Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetics Generation AdvancementROCO:4160 +1.99%70 Days Inventory is 63.54 as of Dec. 2025, which is 0% above its 10-year median of 63.29. GuruFocus rates ROCO:4160 with a GF Score™ of 70/100 and a GF Value™ of NT$51.36 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 179 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks better than 58.66% on this metric.
The historical rank and industry rank for Genetics Generation Advancement's Days Inventory or its related term are showing as below:
ROCO:4160'
s Days Inventory Range Over the Past 10 Years
Min: 33.35 Med: 63.29 Max: 84.94
Current: 52.74
During the past 13 years, Genetics Generation Advancement's highest Days Inventory was 84.94. The lowest was 33.35. And the median was 63.29.
ROCO:4160's Days Inventory is ranked better than 58.66% of 179
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.04
vs ROCO:4160: 52.74
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Genetics Generation Advancement's Inventory Turnover for the
three
months ended in Dec. 2025 was 1.44.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genetics Generation Advancement's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 0.40.
Genetics Generation Advancement (ROCO:4160) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Genetics Generation Advancement's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genetics Generation Advancement's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Genetics Generation Advancement Days Inventory Related Terms
Genetics Generation Advancement Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement Days Inventory Chart
ROCO:4160 vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Days Inventory distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement (ROCO:4160) has a Days Inventory of 63.54 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Genetics Generation Advancement and its competitors. This is near median its historical median of 63.29. Over the past decade, Genetics Generation Advancement's Days Inventory has ranged from 33.35 to 84.94. According to the industry distribution chart, Genetics Generation Advancement ranks #74 out of 179 companies in the Medical Diagnostics & Research industry, placing it in the top 41.3%.
Is Genetics Generation Advancement's Days Inventory too high?
Genetics Generation Advancement's current Days Inventory of 63.54 is near median its 10-year median of 63.29. Over the past 10 years, this metric has ranged from a low of 33.35 to a high of 84.94. The Medical Diagnostics & Research industry median Days Inventory is 65.04. Genetics Generation Advancement's value of 63.54 is 2.3% below this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #74 out of 179 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #74 out of 179 companies for Days Inventory. This puts Genetics Generation Advancement in the upper half of its industry. The industry median Days Inventory is 65.04. Genetics Generation Advancement's value of 63.54 is 2.3% below this benchmark. Historically, Genetics Generation Advancement's own Days Inventory has ranged from 33.35 to 84.94 over the past decade. While the company's 10-year median is 63.29 vs. the industry median of 65.04, Genetics Generation Advancement has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 65.04, based on 179 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current Days Inventory of 63.54 is 2.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 65.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current Days Inventory is 63.54, which is near median its own 10-year median of 63.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.36, compared to a current price of NT$40.95 — trading 20.3% below its estimated fair value. The current Days Inventory is 63.54, which is near median its 10-year median of 63.29 and 2.3% below the Medical Diagnostics & Research industry median of 65.04. Genetics Generation Advancement's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Days Inventory is 63.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$40.95 is trading 20.3% below its estimated GF Value™ of NT$51.36.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Days Inventory: 63.54 (near median its 10-year median of 63.29)
GF Value™: NT$51.36 vs. price of NT$40.95 (20.3% below fair value)
Industry Position: 2.3% below the Medical Diagnostics & Research median (#74 of 179)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
70GF Score
Get the complete analysis for ROCO:4160
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
